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ABSTRACT 
Background: The extent of psychotropic medication use in patients with 
eating disorders worldwide is unknown. 
Objectives: The purposes of this study were to: (1) describe the extent and 
pattern of psychotropic medication use at a private treatment facility for patients 
with eating disorders and (2) describe patient characteristics and treatment out- 
comes at the facility. 
Methods: This retrospective chart review included ata from a private treat- 
ment facility (inpatient or outpatient) for patients with eating disorders in the 
greater Los Angeles area. Data from all patients of any age who attended the 
facility between January 1, 2004, and January 1, 2005, and who met the criteria 
for anorexia nervosa (AN), bulimia nervosa (BN), or eating disorder not other- 
wise specified (ED NOS) defined in the American Psychiatric Association's 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revi- 
sion were included. Two investigators used a consistent chart-review method 
for recording clinical status, including treatment-related adverse effects and 
discharge status (improved, no change, or decompensated from admission). 
Improved was defined as meeting 1 or more of the following criteria: achieved 
ideal body weight, stabilized mood, decreased eating disorder symptoms 
(binge-purge, restrictive, or ritualistic behavior), eating disorder emission, or 
decreased suicidal ideation plus another improvement in this list. 
Results: Data from 60 patients were included (31 with AN, 28 with BN, and 1 
with ED NOS). Ages ranged from 12 to 47 years, and the mean duration of treat- 
ment was 35 days. Fifty-eight (96.7%) patients received apsychotropic agent; 35 
(58.3%) patients were prescribed 2 or more agents concomitantly. Selective 
serotonin reuptake inhibitors (SSRIs) were the most commonly prescribed class 
of psychotropic medication (86.7%), followed by antipsychotics (38.3%). Fluoxetine, 
escitalopram, and aripiprazole were the most commonly prescribed agents 
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(41.7%, 28.3%, and 23.3%, respectively). A total of 63.3% of patients had a comor- 
bid diagnosis of major depressive disorder, with 96.7% of these patients pre- 
scribed an antidepressant. A  discharge, 51.6% of the inpatients and 37.9% of the 
outpatients had improved (AN, 52.6% and 33.3%, respectively; BN, 54.5% and 
41.2%, respectively). Of the patients prescribed an SSRI, 40.4% had improved. In 
the inpatient setting, 35.5% of patients receiving an antipsychotic had improved, 
versus 6.9% in the outpatient setting. 
Conclusions: The results of this retrospective chart review and descriptive 
analysis of data from patients at a private eating disorders treatment facility in 
the United States uggest that psychotropics, particularly antidepressants and 
antipsychotics, were highly utilized, largely to treat comorbid symptoms. 
Fluoxetine, escitalopram, and aripiprazole were the most commonly prescribed 
agents. We observed that psychotropic medication selection was based on 
patient comorbidities and symptom expression and severity. (Curr Ther Res Clin 
Exp. 2005;66:572-588) Copyright © 2005 Excerpta Medica, Inc. 
Key words: psychotropic medication, anorexia nervosa, bulimia nervosa, 
eating disorder, antidepressant, antipsychotic. 
INTRODUCTION 
Roughly 5 to 10 million people in the United States have an eating disorder or a 
disturbance in eating behavior. The estimated lifetime prevalence ofanorexia ner- 
vosa (AN) is 0.5% to 1.0% in US females and 0.05% to 0.1% in US males. 1'2 Of pa- 
tients with a diagnosis of AN, <50% will fully recover despite treatment. 1,2The esti- 
mated mortality rate in people with AN is 0.59% per year, or -5.9% per decade, 
which is -12-fold higher than the annual mortality rate due to all causes of death 
in females aged 15 to 24 years in the general westernized population. 3 The 
estimated mortality rate in males with AN is 5% per year for the first 2 years after 
diagnosis. 3 Patients with eating disorders experience a marked ecrease in quality 
of life due to the development of medical complications, uch as hypovolemia, 
hypokalemia, osteoporosis and fracture, cardiac decompensation, arrhythmia, 
congestive heart failure and/or psychiatric omorbidities. 4 
Bulimia nervosa (BN) is also a public health concern, with an estimated lifetime 
prevalence of 1% to 2% in US females and 0.1% to 0.2% in US males. 5'6 Symptoms 
of BN, such as isolated episodes of bingeing and purging, have been reported in up 
to 40% of female college students. Medical complications ofpurging include elec- 
trolyte abnormalities, cardiac arrhythmia, nd erosion of tooth enamel and the 
esophagus. Drug and alcohol dependence, together with recurrent binge-purge 
behavior, often negatively affects the long-term prognosis of patients with BN. 3,4 
Comorbid psychiatric illnesses add to the morbidity and functional impair- 
ment of patients with eating disorders. Some studies have found lifetime preva- 
lence rates of psychiatric comorbidity--most notably major depressive disorder 
(MDD) and anxiety disorders uch as obsessive-compulsive disorder--to be as 
high as 80% in patients with eating disorders. 7 
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A literature search using MEDLINE (key terms: anorexia nervosa, bulimia net- 
rosa, eating disorders, psychotropic medication use in eating disorders, SSRI use in 
eating disorders, and antipsychotic use in eating disorders; years: 1966-2005) revealed 
evidence-based guidelines, such as the American Psychiatric Association's (APA) 
Practice Guideline for the Treatment of Patients with Eating Disorders 8 and the 
National Institute for Clinical Excellence's (NICE) eating disorder guideline. 9 There 
were also numerous placebo-controlled trials of selective serotonin reuptake 
inhibitors (SSRIs) in the treatment of BN, and open-label trials and case reports 
assessing the use of SSRIs in AN. 10-15 In addition, several case reports and open- 
label trials have assessed the treatment of AN with second-generation antipsy- 
chotics. 16-18 However, we found no published naturalistic studies describing phar- 
macologic intervention i the treatment of eating disorders in clinical practice, or 
of the extent of psychotropic medication use at facilities that treat eating disorders. 
Nutritional rehabilitation and psychotherapy are the main therapeutic nter- 
ventions for both AN and BN, although psychotropic medications are increas- 
ingly used adjunctively. 19The evidence-based guidelines (APA 8 and NICE 9) 
agree that medications should not be used as first-line treatment of AN, and the 
only pharmacologic recommendation concerning the treatment of AN or BN is 
to prescribe an antidepressant, in particular an SSRI. 8,9 The APA guideline 8 rec- 
ommends that antidepressants, such as fluoxetine, be considered in the treat- 
ment of AN only after weight gain has occurred. However, depression, anxiety, 
obsessive behavior, or certain impulse-disorder symptoms might persist. 
Antidepressants may be used as a first-line option in the treatment of BN, if 
used to reduce the frequency of disturbed eating behaviors, such as bingeing 
and purging. Specific antidepressant agents that have been found to be effica- 
cious in managing BN in double-blind, placebo-controlled studies include 
imipramine, desipramine, amitriptyline, fluoxetine, bupropion, trazodone, and 
several monoamine oxidase inhibitors. 8,9 
Psychotropic medications are often prescribed to treat comorbid psychiatric 
symptoms (eg, depressed or anxious mood, obsessive-compulsive symptoms) 
and improve ating behavior. 7 SSRIs are the most well-studied category of medi- 
cations used in the treatment of eating disorders, with fluoxetine being the only 
medication approved by the US Food and Drug Administration for the treatment 
of BN. However, other antidepressants, anxiolytics, mood stabilizers, and anti- 
psychotics are also prescribed for both AN and BN. 10'11'20 
The purposes of this report were to: (1) compare the extent and pattern of psy- 
chotropic medication use at a private treatment facility for patients with eating 
disorders with those described in the literature, including treatment guidelines, 
and (2) describe patient characteristics and treatment outcomes at the facility. 
MATERIALS AND METHODS 
This retrospective chart review analyzed information from the patient database 
at a private eating disorders treatment facility in Rosemead, California. Data 
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from male and female patients of any age with a diagnosis of AN or BN as 
defined in the APA's Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition, Text Revision (DSM-IV-TR) 6 and admitted to the facility (inpatient or out- 
patient) between January 1, 2004, and January 1, 2005, were included. All re- 
suits were based on the patient's first admission only. The study protocol was 
approved by the medical staff at the facility and the institutional review board 
at the School of Medicine and Ardent Health Care, University of Southern 
California, Los Angeles, California (the parent company of the facility), allowing 
patient information to be obtained for the purposes of the chart review. 
Informed consent was not required by either institution and thus was not 
obtained. Patient confidentiality was maintained by randomly assigning a num- 
ber to each patient in the database without recording specific identifying infor- 
mation, such as initials or the referring facility. 
Treatment Facility 
The eating disorders treatment facility in this study was a private multimodal 
treatment facility. In their eating disorders treatment program, patients received 
individual, group, and family therapy; pharmacotherapy; and nutritional ther- 
apy through a multidisciplinary team approach consisting of psychotherapists, 
registered nurses, dietitians, and psychiatrists, in an inpatient or outpatient set- 
ting. The inpatient setting involved intensive, 24-hour therapy. Patients had the 
opportunity to receive step-down care from the inpatient setting to the outpa- 
tient setting. Step-down care consisted of a partial hospitalization program 
(PHP) or intensive outpatient program (IOP). PHP allowed patients to spend 8 
to 10 hours a day, 6 days a week at the facility, and to spend their evenings at 
their places of residence. In IOP, the final step-down process, patients tayed at 
the clinic 4 to 8 hours a day, 3 to 5 days a week, which enabled them to become 
reacclimated to society and their lives outside the clinic. 
As in most private eating disorder treatment facilities, the facility in this 
study was contracted with numerous insurance carriers, allowing the majority 
of patients to receive care through insurance coverage. The formulary at the 
facility was unrestricted; that is, psychiatrists prescribed treatments based on 
their preferences and clinical judgment. There was no consistent clinical phar- 
macy input to influence prescribing except for a 6-week clinical rotation by one 
of the investigators (K.G.). Patients were assessed by psychiatrists board certi- 
fied in adult and/or child psychiatry. 
Literature Search and Study Design 
Before the chart review was performed, a database-management expert was 
consulted by the investigators to design a data-collection tool. The investiga- 
tors followed a consistent method for chart review, the specific data to be col- 
lected was specified, and the criteria for improvement was established. 
Information was collected from each patient chart by an investigator and 
entered into the predesigned database (Access 2003, Microsoft Corp., Redmond, 
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Washington). Information collected included age, sex, height, weight, admission 
status (inpatient vs outpatient), diagnosis (including other psychiatric diag- 
noses), length of stay (LOS), and current or previously prescribed medications 
and adverse ffects. Eating disorder diagnoses that were recorded for the study 
were based on the diagnostic impressions documented in the patient chart by 
the medical director or his designated appointee. 
Several additional patient characteristics were also recorded, including 
previous hospitalization for an eating disorder; drug, alcohol, laxative, and 
stimulant abuse; self-mutilating behaviors; depressed mood; obsessive- 
compulsive tendencies; uicidal ideation or attempt; anxiety; sexual or physical 
abuse; excessive exercising; and lability/impulsivity. Daily progress notes 
and weekly multidisciplinary treatment plans written by nursing staff, psy- 
chologists, social workers, a dietitian, and a board-certified psychiatrist were 
reviewed and analyzed by the investigators. Information concerning 
improvement s atus was gathered from progress notes by the investigators, 
with confirmation of improvement status obtained by reviewing the dis- 
charge summary. Discharge status was recorded as improved, no change, or 
decompensated from admission. Patients were classified as improved if they 
met 1 or more of the following criteria: achieved ideal body weight, stabilized 
mood, decreased eating disorder symptoms (binge-purge, restrictive, or rit- 
ualistic behavior), eating disorder emission, or decreased suicidal ideation 
plus another improvement in this list. There was no objective rating of symp- 
tom severity. 
Statistical Analysis 
Descriptive statistics were generated to determine the distribution of psy- 
chotropic medication use. The association between (eating disorder) diagnosis 
and sex, diagnosis and admission status (inpatient or outpatient), admission 
status and discharge status (improved, no change, or decompensated), iagno- 
sis and discharge status, and medication class (eg, SSRI, antipsychotic) and dis- 
charge status were assessed using the )~2 test. The intragroup difference in the 
mean LOS by discharge status was assessed using 1-way analysis of variance. 
All analyses were conducted using SAS version 9.1 (SAS Institute Inc., Cary, 
North Carolina) at the 0.05 significance l vel. 
RESULTS 
Sixty charts met the criteria for review (51 females, 9 males) (Tables I and If). 
Thirty-one patients had a DSM-IV-TR6-defined diagnosis of AN, and 28 had a diag- 
nosis of BN. One patient had a diagnosis of eating disorder not otherwise spec- 
ified (ED NOS). Patients' ages ranged from 12 to 46 years (means: BN, 24.6 years; 
AN, 20.4 years). A significantly higher number of male patients had a diagnosis 
of AN compared with BN (8 [25.8%] vs 1 [3.6%]; P< 0.018). The mean LOS was 
35 days (BN, 32 days; AN, 39 days). In the AN group, a statistically similar num- 
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Table II. Demographic and baseline clinical characteristics of the study patients (N = 60). 
BN AN ED NOS 
Characteristic (n = 28) (n = 31) (n = 1) 
Age, mean, y 24.6 20.4 17.0 
Sex, no. (%) 
Female 27 (96.4) 23 (74.2) 1 
Male 1 (3.6) 8 (25.8)* - 
Height, mean, cm 162.9 1 61.9 1 62.6 
Weight, mean, kg 69.4 42.9 59.4 
Admission status, no. (%) 
Inpatient 11 (39.3) 19 (61.3) 1 
Outpatient 17 (60.7) 12 (38.7) - 
Comorbid psychiatric 
condition, no. (%)t 
Major depressive disorder 17 (60.7) 14 (45.2) 1 
Bipolar disorder 5 (17.9) 3 (9.7) 0 
Anxiety disorder { 2 (7.1) 5 (1 6.1) 2 
Schizophrenia 0 1 (3.2) 0 
Other risk factors, no. (%)t 
Depressed mood 21 (75.0) 28 (90.3) 1 
Drug abuse 20 (71.4) 0 0 
Anxiety 19 (67.9) 22 (71.0) 1 
Excessive exercising 16 (57.1) 15 (48.4) 0 
Suicidal ideation or attempt 16 (57.1) 11 (35.5) 1 
Previous hospitalization 15 (53.6) 20 (64.5) 1 
Self-mutilation 14 (50.0) 6 (19.4) 1 
Sexual/physical abuse 14 (50.0) 6 (19.4) 0 
Obsessive-compulsive tendencies 13 (46.4) 10 (32.3) 1 
Alcohol abuse 10 (35.7) 3 (9.7) 0 
Stimulant abuse 10 (35.7) 3 (9.7) 0 
Laxative abuse 9 (32.1) 5 (1 6.1) 0 
Lability/impulsivity 4 (14.3) 15 (48.4) 1 
BN = bulimia nervosa; AN = anorexia nervosa; ED NOS = eating disorder not otherwise specified. 
*P < 0.018 versus BN. 
tSome patients had >1 comorbid psychiatric condition or risk factor. 
{Includes panic disorder, obsessive-compulsive disorder, and/or posttraumatic stress disorder. 
ber of patients were treated in the inpatient setting compared with the outpa- 
tient setting (19 [61.3%] vs 12 [38.7%]). 
A statistically similar proportion of patients in each group had a comorbid 
diagnosis of MDD 03N, 17 [60.7%]; AN, 14 [45.2%]), and 31 (96.7%) patients with 
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MDD were prescribed an antidepressant. Of the 60 patients, 16 (26.7%) (BN, 6 
[21.4%]; AN, 10 [32.3%]) did not have a comorbid psychiatric diagnosis. The 1 pa- 
tient with a diagnosis of ED NOS had comorbid diagnoses of MDD, obsessive- 
compulsive disorder, and adjustment disorder. One (3.2%) patient with AN had 
a diagnosis of schizophrenia, and 8 patients (3 [9.7%] with AN and 5 [17.9%] 
with BN) each had a diagnosis of bipolar disorder or an anxiety disorder (panic 
disorder, obsessive-compulsive disorder, and/or posttraumatic stress disorder). 
All of the patients with a comorbid anxiety disorder were prescribed at least 
1 antidepressant (Tables II and III). 
Fifty-eight (96.7%) of the 60 patients received a psychotropic agent during 
treatment. Thirty-five (58.3%) patients were prescribed 2 or more concomitant 
Table III. Psychotropic medications prescribed at any point during facil ity stay 
(N = 60).* 
Psychotropic No. (%) Psychotropic No. (%) 
Medication of Patients Medication of Patients 
SSRIs Mood stabilizers 
Fluoxetine 25 (41.7) Topiramate 3 (5.0) 
Escitalopram 1 7 (28.3) Valproate 2 (3.3) 
Sertraline 8 (13.3) Lithium 2 (3.3) 
Paroxetine 2 (3.3) Oxcarbazepine 2 (3.3) 
Fluvoxamine 2 (3.3) Lamotrigine 2 (3.3) 
Gabapentin 1 (1.7) 
Citalopram 2 (3.3) Tiagabine 1 (1.7) 
Other antidepressants Anxiolytics 
Trazodone 5 (8.3) Lorazepam 9 (15.0) 
Bupropion 4 (6.7) Clonazepam 4 (6.7) 
Venlafaxine 3 (5.0) Buspirone 2 (3.3) 
Mirtazapine 2 (3.3) Temazepam 1 (1.7) 
Nefazodone 1 (1.7) Alprazolam 1 (1.7) 
Antipsychotics Others 
Aripiprazole 14 (23.3) Zolpidem 5 (8.3) 
Diphenhydramine 3 (5.0) 
Quetiapine 7 (11.7) Methylphenidate 2 (3.3) 
Olanzapine 3 (5.0) Naltrexone 1 (1.7) 
Risperidone 2 (3.3) Atomoxetine 1 (1.7) 
Ziprasidone 2 (3.3) Mixed amphetamine salts 1 (1.7) 
Haloperidol 2 (3.3) Modafinil 1 (1.7) 
SSRIs = selective serotonin reuptake inhibitors. 
*Some patients received ~1 psychotropic medication. 
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psychotropic medications. SSRIs were the most commonly prescribed class of 
psychotropic agents, with 52 (86.7%) patients receiving an SSRI at some point 
during their treatment, followed by the antipsychotics (23 [38.3%]). Fluoxetine 
was the most commonly prescribed psychotropic medication (25 [41.7%] pa- 
tients), followed by escitalopram (17 [28.3%]), and aripiprazole (14 [23.3%]) 
(Table llI). These numbers reflect the total number of individual patients who 
received each medication at any point during their stay at the facility. Twelve 
patients were given trials of multiple medications throughout their admission. 
For example, 1 patient was given consecutive trials of sertraline, escitalopram, 
and fluoxetine during the same hospital stay. Prescribing patterns did not differ 
significantly between diagnoses. 
Seven medications that are contraindicated in patients with eating disorders 
were used at the clinic. Six of 7 medications were prescribed before admission 
to the facility, and their use was continued after admission. These medications in- 
cluded bupropion, 21 stimulants (eg, methylphenidate, mixed amphetamine salts), 22 
and weight-loss products (eg, sibutramine). 22
A large percentage of patients discontinued treatment against the medical 
advice of the treatment team in the inpatient (6 [19.4%]) and outpatient (5 [17.2%]) 
settings. Ten (32.3%) patients in the inpatient setting and 13 (44.8%) in the out- 
patient setting experienced no change in status from admission to discharge. 
Sixteen (51.6%) patients in the inpatient unit had a documented improvement 
(AN, 10 [52.6%]; BN, 6 [54.5%]) and 11 (37.9%) patients in the outpatient setting 
improved (AN, 4 [33.3%]; BN, 7 [41.2%]). Of the 52 patients prescribed an SSRI, 
21 (40.4%) had a documented improvement (both inpatient and outpatient). In 
the inpatient setting, 11 (35.5%) patients receiving an antipsychotic had docu- 
mented improvement compared with 2 (6.9%) in the outpatient setting (Figure). 
DISCUSSION 
Based on the literature search, this is the first retrospective r view of the extent 
of psychotropic medication use in all eating disorder diagnoses at an eating dis- 
orders treatment facility. A 1987 study 23 reviewed patient characteristics and 
medication use in AN over 3 time periods (1958-1962, 1968-1972, and 1978- 
1982) and found a significant increase in the use of antidepressants (from 4% to 
58%) and antipsychotics (from 0% to 19%) from 1958-1962 to 1978-1982. 
The demographic characteristics of the patients in our study reflect he cur- 
rent epidemiologic data regarding AN and BN (predominately females aged 
12-47 years). 1-3,6 One exception was the significantly higher number of males 
presenting with a diagnosis of AN compared with BN. This finding is in contrast 
to published literature stating that males account for -5% to 10% of patients 
with AN and -10% to 15% of patients with BN in US community samples. 24 
In the present study, patients with BN had a considerably higher rate of 
symptom expression representing poor impulse control (eg, suicidal ideation, 
self-mutilation, and drug and alcohol abuse) compared with patients with a 
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diagnosis of AN. BN is often associated with personality disorders, particularly 
those featuring impaired impulse control and rigid thinking (eg, borderline per- 
sonality disorder). 25 In patients with a diagnosis of BN, substance abuse has 
been associated with increased prevalences of attempted suicide, stealing, and 
promiscuity compared with patients with BN who did not have a history of sub- 
stance abuse. 25 
In the present study, patients with AN or BN expressed a high prevalence of 
depressed symptoms, with 31 (52.5%) patients with AN or BN having a comor- 
bid diagnosis of MDD. These findings are supported by those from a review by 
Pollice et al, 26 who found high prevalences of comorbid mood and anxiety dis- 
orders in a population with eating disorders. 
Our study found a high rate of psychotropic medication prescribing. The 
functional impairment caused by psychiatric symptoms econdary to AN and 
BN seemed sufficient for physicians to prescribe medications at the facility; 
that is, 16 (26.7%) of 60 patients did not have a DSM-IV-TR-defined comorbid 
psychiatric diagnosis, yet 58 (96.7%) were prescribed medication. Psychotropic 
medication prescribing seemed to be based predominately on patient charac- 
teristics, symptom expression, and comorbid diagnoses. A high percentage of
patients (86.7%) were prescribed an SSRI, most notably fluoxetine or escitalo- 
pram. Although the literature shows mixed results regarding the efficacy of anti- 
depressants in AN, 27 26 (83.9%) of the 31 patients with a diagnosis of AN in our 
study were prescribed an SSRI. 
Two placebo-controlled studies of the use of fluoxetine in 3112 and 3528 patients 
with AN found a minimal, statistically nonsignificant effect on weight gain, eating 
symptoms, or depressive symptoms compared with placebo in the inpatient set- 
ting. However, in another study, when administered after discharge from inpatient 
treatment, fluoxetine had a significant beneficial effect in terms of preventing 
relapse. 19 In 1 double-blind, placebo-controlled trial, 35 patients with AN were 
randomly assigned to receive fluoxetine 10 to 30 mg/d (16 patients) or placebo 
(19 patients) (control) after weight gain had occurred in the inpatient setting, and 
they were observed as outpatients for 52 weeks. Ten of the 16 (62.5%) patients 
receiving fluoxetine had a relapse reduction, defined as a significant increase in 
weight and a reduction in core eating disorder symptoms, obsessive thoughts, 
and depressed and anxious mood compared with controls. 28 Patients with AN in 
our study received fluoxetine 5 to 60 mg/d (mean dose, 20.4 mg/d). 
The current literature suggests that the efficacy of fluoxetine in the treatment 
of BN requires doses as high as 60 mg/d to reduce the number of binge-purge 
episodes per week. 14,15 In a longer-term single-blind, placebo-controlled trial, 
150 patients with BN randomized to receive fluoxetine 60 mg/d for up to 52 weeks 
experienced a significantly onger time to relapse compared with those receiving 
placebo. 29 Patients with BN in our study received fluoxetine 10 to 80 mg/d (mean 
dose, 24.5 mg/d). 
The present study found a high rate of SSRI prescribing in the patients with 
BN (25/28 [89.3%]), with fluoxetine representing 12 of these prescriptions. Cur- 
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rent literature supports the use of antidepressants concomitantly with psycho- 
therapy in the treatment of BN. Two systematic reviews of the use of antide- 
pressants in BN have been published. 16,3° A Cochrane database system review 16 
included 19 placebo-controlled trials comparing the use of antidepressants with 
that of placebo in patients with BN. A review by Bacaltchuk et al 3° included 
12 placebo-controlled trials assessing the use of antidepressants together with 
psychological pproaches in 590 patients with BN. Both reviews found that anti- 
depressants reduced BN symptoms, most notably the binge-purge cycle, and 
prolonged remission of the eating disorder. 16,3° In addition, antidepressant use 
was found to be associated with a 50% to 70% reduction in binge-purge pi- 
sodes in studies in which patients were treated for 4 to 8 weeks. 16 
Twenty-three of the 60 (38.3%) patients in our study were prescribed an 
antipsychotic. The rate of prescribing second-generation a tipsychotics was 
high, with 14 (23.3%) patients receiving aripiprazole and 7 (11.7%) patients 
receiving quetiapine. To date, no randomized, placebo-controlled trials assess- 
ing the efficacy and tolerability of second-generation antipsychotics in the man- 
agement of AN or BN have been published. 
Based on the literature search, only case reports and open-label trials, 
mostly of olanzapine, have reported the efficacy of the second-generation 
antipsychotics in the treatment of AN. 17'18'31 Those trials have reported some 
decrease in agitation and resistance to treatment, diminished anxiety and obses- 
sive thinking about food, weight gain, and improved mealtime behavior. 17,18,31 
However, because of their propensity to cause excessive weight gain and 
metabolic abnormalities, many second-generation a tipsychotics are consid- 
ered unfavorable treatment options for eating disorders. 17,18,31 
Ziprasidone is considered weight neutral, 13 and is associated with a lower 
risk for metabolic omplications compared with other second-generation agents, 
but it was not highly prescribed (2/60 [3.3%]), likely due to its association 
with a greater isk for cardiac adverse ffects, including corrected QT interval 
(QTc) prolongation, compared with that of other second-generation a tipsy- 
chotics. 32 Aripiprazole might be considered more favorable in patients with 
eating disorders due to its reported ecreased risks for weight gain and metabolic 
complications compared with those of olanzapine, and decreased apparent risk 
for QTc prolongation compared with that of ziprasidone, 13'33 but more studies 
are needed to confirm those results. 
Study Limitations 
Several imitations were encountered during this study, most notably the 
lack of consistently applied objective measures of improvement, small sample 
size, and limited external validity, given that our study represented only 1 pri- 
vate eating disorder treatment facility. Because the formulary at the facility was 
unrestricted, that is, psychiatrists prescribed treatments based on their prefer- 
ences and clinical judgment, here may have been individual prescribing biases. 
Prescribers receive information concerning drug therapy from professional con- 
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ferences, industry-sponsored symposia, medical journals, and Web-based rug in- 
formation programs (personal communication, Medical Director, Wakelin McNeel, 
2005). 
We were also unable to ensure medication adherence in the outpatient set- 
ting because the medications were not dispensed by the outpatient clinic. For 
this reason, and because patients received both psychotropic medications and 
psychotherapy throughout their stay at the facility, it was not possible to deter- 
mine whether discharge results and treatment outcomes were the results of 
medications or psychotherapy. There was no standardized rating scale or 
objective measurement for the documentation of improvement used by the 
staff at the facility, and there was some inconsistency in documentation f the 
purpose of medication selection and ongoing tolerability of the medications. 
Recommendat ions  
The results of this retrospective chart review identified the following recom- 
mendations for the facility: 
1. Implement a process for more systematic assessment of the effectiveness 
of the medications. For example, standardized rating scales (eg, Clinical 
Global Impression, 34Beck Depression Inventory, 35Yale Brown Obsessive- 
Compulsive Scale 36) can be used at baseline and at weekly medication as- 
sessments to determine the effectiveness of antidepressants in treating 
specific comorbidities. 37 
2. Consistently assess medication tolerability by documenting whether com- 
mon and/or serious adverse ffects pecific to antidepressants (eg, dizzi- 
ness, orthostasis with quetiapine; nausea nd vomiting with aripiprazole) 
are present. 
3. Administer standardized forms that document eating disorder sympto- 
matology (eg, Eating Attitudes Test, 38 Eating Disorder Inventory-239) at 
patient admission and discharge. These forms allow for more objective 
documentation f improvement versus decompensation in patients with 
eating disorders compared with descriptive reports in the progress notes. 
4. Ensure treatment adherence by administering treatments with supervi- 
sion at the clinic. 
5. Due to the high rate of prescribing of second-generation antipsychotics 
found at this facility, further investigation of their use for the treatment of
eating disorders is needed. 
CONCLUSIONS 
The results of this retrospective data analysis in patients with eating disorders 
at a private eating disorders treatment facility suggest that psychotropics, par- 
ticularly antidepressants and antipsychotics, were highly utilized, mostly to 
treat comorbid symptoms. Fluoxetine, escitalopram, and aripiprazole were the 
most commonly prescribed agents. 
585 
CURRENT THERAPEUTIC RESEARCH 
ACKNOWLEDGMENTS 
Investigator Julie A. Dopheide, PharmD, has received past honorar ia and con- 
suiting fees from AstraZeneca Pharmaceut icals  LP, Wilmington, Delaware; 
Abbott  Laborator ies Inc., Abbott  Park, Illinois; Bristol-Myers Squibb Company, 
Princeton, New Jersey; Ciba-Geigy (now Novartis Pharmaceut icals  Corporation, 
East Hanover, New Jersey), Takeda Pharmaceut icals  North America, Inc., 
Lincolnshire, Illinois; Novart is Pharmaceut ica ls  Corporation; and Janssen 
Pharmaceutica,  Inc., Titusville, New Jersey. 
Special thanks to Joanne Wu, MS, and Michael Goode, MS, School of 
Pharmacy, University of Southern California, Los Angeles, California, who aided 
in statistical analysis and database design, respectively. We also thank the fol- 
lowing people for making this s tudy possible: Wakelin McNeel, MD; Patricia 
Pitts, PhD; and Letty Lozano, RN, MS. 
REFERENCES 
1. Shisslak CM, Crago M, Estes LS. The spectrum of eating disturbances. IntJEatDisord. 
1995; 18:209-219. 
2. National Eating Disorders Association Web site. Available at: http://www.national 
eatingdisorders.org. Accessed December 14, 2005. 
3. Nielsen S, Moller-Madsen S,Isager T, et al. Standardized mortality in eating disorders-- 
a quantitative summary of previously published and new evidence. JPsychosom Res. 
1998;44:413-434. 
4. Comerci GD. Medical complications of anorexia nervosa nd bulimia nervosa. Med 
Clin North Am. 1990;74:1293-1310. 
5. Fairburn CG, Welch SL, Norman PA, et al. Bias and bulimia nervosa: How typical are 
clinic cases? Am JPsychiatry. 1996;153:386-391. 
6. American Psychiatric Association, Task Force on DSM-IV. Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, 
DC: American Psychiatric Association; 2000. 
7. Ebeling H, Tapanainen P, Joutsenoja A, et al, for the Finnish Medical Society 
Duodecim. A practice guideline for treatment of eating disorders in children and ado- 
lescents. Ann Med. 2003;35:488-501. 
8. American Psychiatric Association Work Group on Eating Disorders. Practice guide- 
line for the treatment of patients with eating disorders (revision). Am J Psychiatry. 
2000;157(Suppl 1):1-39. 
9. National Institute for Clinical Excellence. Eating Disorders: Core Interventions in the 
Treatment and Management Of Anorexia Nervosa, Bulimia Nervosa, and Related 
Eating Disorders, Clinical Guideline 9. London, UK: 2004. 
10. Schmidt U, Cooper P J, Essers H, et al. Fluvoxamine and graded psychotherapy in the 
treatment of bulimia nervosa: A randomized, double-blind, placebo-controlled, mul- 
ticenter study of short-term and long-term pharmacotherapy combined with a 
stepped care approach to psychotherapy. J Clin Psychopharmacol. 2004;24:549-552. 
11. Miano W, Petrella C, Sabatino C, Capasso A. Treatment of bulimia nervosa with ser- 
traline: A randomized controlled trial. Adv Ther. 2004;21:232-237. 
586 
K.N. Gable and J.A. Dopheide 
12. Attia E, Haiman C, Walsh BT, Flater SR. Does fluoxetine augment he inpatient reat- 
ment of anorexia nervosa? Am J Psychiatry. 1998; 155:548-551. 
13. Casey DE, Haupt DW, Newcomer JW, et al. Antipsychotic-induced weight gain and 
metabolic abnormalities: Implications for increased mortality in patients with schizo- 
phrenia. J Clin Psychiatry. 2004;65(Suppl 7):4-20. 
14. Goldbloom DS, Olmsted M, Davis R, et al. A randomized controlled trial of fluoxetine 
and cognitive behavioral therapy for bulimia nervosa: Short-term outcome. Behav 
Res Ther. 1997;35:803-811. 
15. Goldstein D J, Wilson MG, Thompson VL, et al, for the Fluoxetine Bulimia Nervosa 
Research Group. Long-term fluoxetine treatment of bulimia nervosa. Br J Psychiatry. 
1995; 166: 660-666. 
16. Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia ner- 
vosa. Cochrane Database Syst Rev. 2001;(4):CD003391. 
17. La Via MC, Gray N, Kaye WH. Case reports of olanzapine treatment of anorexia ner- 
vosa. Int J Eat Disord. 2000;27:363-366. 
18. Malina A, Gaskill J, McConaha C, et al. Olanzapine treatment of anorexia nervosa: A 
retrospective study. Int J Eat Disord. 2003;33:234-237. 
19. Gowers S, Bryant-Waugh R. Management of child and adolescent eating disorders: 
The current evidence base and future directions. J Child Psychol Psychiatry. 
2004;45:63--83. 
20. Prozac (fluoxetine hydrochloride) [product information]. Indianapolis, Ind: Eli Lilly 
and Company; 2005. Available at: http://pi.l i l ly.com/us/prozac.pdf. Accessed Decem- 
ber 1, 2005. 
21. Wellbutrin XL (bupropion hydrochlor ide xtended-release tablets)  [product in- 
formation]. Research Triangle Park, NC: GlaxoSmithKline; 2005. Available at: 
http: / /us.gsk.com/products/assets/us_wel lbutr inXL.pdf .  Accessed December 1, 
2005. 
22. Adderall XR (mixed amphetamine salts) [product information]. Shire US Inc; 2005. 
Available at: http: / /www'adderal lxr 'c°m/assets/pdf /prescr ib ing- inf°rmat i°n'pdf"  
Accessed December 1, 2005. 
23. George DT, Weiss SR, Gwirtsman HE, Blazer D. Hospital treatment of anorexia ner- 
vosa: A 25 year retrospective study from 1958 to 1982. Int J Eat Disord. 1987;6: 
321-330. 
24. Carlat D J, Camago CA Jr, Herzog DB. Eating disorders in males: A report on 135 pa- 
tients. Am J Psychiatry. 1997;154:1127-1132. 
25. Rosenvinge JH, Martinussen M, Ostensen E. The comorbidity of eating disorders and 
personal ity disorders: A meta-analytic review of studies published between 1983 and 
1998. Eat Weight Disord. 2000;5:52-61. 
26. Pollice C, Kaye WH, Greeno CG, Weltzin TE. Relationship of depression, anxiety, and 
obsessional ity to state of illness in anorexia nervosa. Int J Eat Disord. 1997;21: 
367-376. 
27. Kruger S, Kennedy SH. Psychopharmacotherapy of anorexia nervosa, bulimia ner- 
vosa, and binge-eating disorder. JPsychiatry Neurosci. 2000;25:497-508. 
28. Kaye WH, Nagata T, Weltzin TE, et al. Double-blind placebo-control led a ministration 
of fluoxetine in restricting- and restricting-purging-type anorexia nervosa. Biol 
Psychiatry. 2001;49:644-652. 
29. Romano S J, Halmi KA, Sarkar NP, et al. A placebo-control led study of fluoxetine in 
continued treatment of bulimia nervosa after successful acute fluoxetine treatment. 
Am J Psych iatry. 2002;159:96-102. 
587 
CURRENT THERAPEUTIC RESEARCH 
30. Bacaltchuk J, Trefiglio RP, Oliveira IR, et al. Combination of antidepressants and psy- 
chological treatments for bulimia nervosa: A systemic review. Acta Psychiatr Scand. 
2000;101:256-267. 
31. Powers PS, Santana CA, Bannon YS. Olanzapine in the treatment of anorexia nervosa: 
An open label trial. Int J Eat Disord. 2002;32:146-154. 
32. Stimmel, GL, Gutierrez MA, Lee V. Ziprasidone: An atypical antipsychotic drug for the 
treatment of schizophrenia. Clin Ther. 2002;24:21-37. 
33. DeLeon A, Pate] NC, Crismon ML. Aripiprazole: A comprehensive r view of its phar- 
macology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649-666. 
34. Guy W. Clinical Global Impressions (CG1). In: American Psychiatric Association, Task 
Force for the Handbook of Psychiatric Measures, eds. Handbook of Psychiatric 
Measures. Washington, DC: American Psychiatric Association; 2000:100-102. 
35. Beck AT, Ward CH, Mendelson M, et al. An inventory for measuring depression. Arch 
General Psychiatry. 1961;4:561-571. 
36. Goodman WK, Price LH, Rasmussen SA, eta]. The Yale-Brown Obsessive Compulsive 
Scale. I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46:1006-1011. 
37. Sajatovic M, Ramirez LE Rating Scales in Mental Health. Hudson, Oh: Lexi-Comp, Inc; 
2001:49-50, 78, 164-165. 
38. Garner DM, Olmsted MP, Bohr Y, Garfinkel PE. The eating attitudes test: 
Psychometric features and clinical correlates. Psychol Med. 1982;12:871-878. 
39. Garner DM. Eating Disorder Inventory-2: Professional Manual 1991. Odessa, Fla: 
Psychological Assessment Resources; 1991. 
Address correspondence to: Julie A. Dopheide, PharmD, School of Pharmacy, 
University of Southern California, 1985 Zonal Avenue, Los Angeles, CA 90089. 
E-mail: dopheide@usc.edu 
588 
